Holen Sie sich die Stockscreener-App
8.90
5.62%
-0.53
Handel nachbörslich:
8.90
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet - MSN
Zevra Therapeutics’ Earnings Call: Optimism Amid Challenges - MSN
Zevra Therapeutics’ SWOT analysis: stock soars on MIPLYFFA success, pipeline potential - Investing.com
Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability - TipRanks
Zevra Therapeutics at Canaccord Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
JMP Securities maintains Market Outperform on Zevra, lowers PT to $18. - AInvest
Price Channel Expanding on Zevra Therapeutics Inc.’s ChartDividend Hike & Safe Entry Point Alerts - 선데이타임즈
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2025 Earnings Call Transcript - Insider Monkey
Zevra Therapeutics price target lowered to $18 from $19 at Citizens JMP - TipRanks
Zevra Therapeutics shares fall 9.01% premarket despite Q2 profit and revenue growth. - AInvest
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP - Investing.com
Zevra Therapeutics shares fall 10.54% premarket despite Q2 revenue beating estimates. - AInvest
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Zevra Revenue Jumps 486 Percent in Q2 - AOL.com
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: - GuruFocus
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
Zevra Therapeutics Reports Strong Q2 2025 Results - TipRanks
Zevra Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Zevra Therapeutics' Q2 2025 Earnings Call: Unraveling Contradictions in Patient Enrollment Strategies and Reimbursement Timelines - AInvest
Zevra Therapeutics (ZVRA) Reports Strong Q2 2025 Financials - GuruFocus
Transcript : Zevra Therapeutics, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Zevra Therapeutics Outpaces Earnings Estimates And Investor Optimism Builds - Finimize
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Zevra Therapeutics Q2 2025 misses EPS, revenue shines - Investing.com
ZEVRA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Zevra Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Zevra Q2 2025 net revenue at $25.9mln, arimoclomol approval sought in EU - AInvest
Zevra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zevra Therapeutics reports Q2 EPS $1.21, consensus $1.38 - TipRanks
Zevra Therapeutics Q2 Swing to Profits, Revenue Rises - MarketScreener
Zevra Therapeutics earnings missed by $2.25, revenue topped estimates - Investing.com Canada
Zevra Therapeutics falls as significant earnings miss overshadows revenue beat - Investing.com Nigeria
Zevra Therapeutics' Q2 Earnings Outperformance and Strategic Momentum in Rare Disease Therapies: A Deep Dive into Long-Term Investment Viability - AInvest
Zevra Therapeutics Q2 revenue beats estimates - MarketScreener
XRP Predicted to Surge 400% Amid New Update - AInvest
Zevra Therapeutics Inc options imply 12.4% move in share price post-earnings - TipRanks
Those who invested in Zevra Therapeutics (NASDAQ:ZVRA) three years ago are up 102% - Yahoo Finance
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates - Nasdaq
Does Zvra plan to issue more stock? - AInvest
Zevra ZVRA 2025Q2 Earnings Preview Potential Upside on Data-Driven Regulatory Strategy - AInvest
What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing' - Yahoo Finance
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference | ZVRA Stock News - GuruFocus
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Rare Disease Innovator Zevra Therapeutics Sets Key Investor Presentation at Major Growth Conference - Stock Titan
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth - sharewise.com
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call - 富途牛牛
Zevra Therapeutics to report Q2 2025 results on Aug 12. - AInvest
Quant Funds Rotate Into Zevra Therapeutics Inc. StockStock Screener With Smart Filters Highlights Top Picks - metal.it
What are the latest earnings results for Zevra Therapeutics Inc.Extraordinary market timing - Jammu Links News
Zevra Therapeutics Inc. Stock Analysis and ForecastExponential return rates - Jammu Links News
What catalysts could drive Zevra Therapeutics Inc. stock higher in 2025Unlock powerful trading signals and alerts - Jammu Links News
What is Zevra Therapeutics Inc. company’s growth strategyDiscover top stock picks for aggressive growth - Jammu Links News
What is the risk reward ratio of investing in Zevra Therapeutics Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
What are analysts’ price targets for Zevra Therapeutics Inc. in the next 12 monthsUnlock hidden market opportunities today - Jammu Links News
Should I hold or sell Zevra Therapeutics Inc. stock in 2025Free Investment Community - Jammu Links News
How many analysts rate Zevra Therapeutics Inc. as a “Buy”Outstanding capital growth - Jammu Links News
Does Zevra Therapeutics Inc. stock perform well during market downturnsFree Market Volatility Navigation Tips - Jammu Links News
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):